EuCorVac-19
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
20 sept. 2022 21h31 HE | POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
EuCorVac-19
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
06 févr. 2022 22h18 HE | POP Biotechnologies, Inc.
BUFFALO, N.Y., Feb. 06, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a...
logo.jpg
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
20 juil. 2021 09h00 HE | Zylö Therapeutics
Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...
Logo.PNG
Veritas Pharma Provides Corporate Update on Q2 2018
31 mai 2018 03h10 HE | Veritas Pharma Inc.
VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to provide a corporate update on its...
Earth Science Tech,
Earth Science Tech, Inc. Initiates Pre-Launch on its MSN-2 Human Clinical Trials with Clinique Sante Amite
14 nov. 2017 12h00 HE | Earth Science Tech, Inc.
Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp...